Evidence map›Paper›PMID 42373435›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2026

[Clinical strategies and indication expansion of interventional ultrasonography ablative therapy for hepatic tumors].

Y G Liang, H Y Wang, Q Y Zhao, T A Jiang

Abstract readReviewEnglish Abstract
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Y G LiangThe First Affiliated Hospital of Zhejiang University School of Medicine, Department of Ultrasound Medicine, Hangzhou 310003, China.
H Y WangThe First Affiliated Hospital of Zhejiang University School of Medicine, Department of Ultrasound Medicine, Hangzhou 310003, China.
Q Y ZhaoThe First Affiliated Hospital of Zhejiang University School of Medicine, Department of Ultrasound Medicine, Hangzhou 310003, China.
T A JiangThe First Affiliated Hospital of Zhejiang University School of Medicine, Department of Ultrasound Medicine, Hangzhou 310003, China.

Funding

The Key Research and Development Project of Zhejiang Province 2024C03092
6 · The paper itself

Abstract

Thermal ablation has become an important treatment option for early-stage hepatocellular carcinoma with the development of interventional ultrasound technology. However, in the treatment of medium-to-large-volume tumors, intrahepatic cholangiocarcinoma, and high-risk anatomical sites, it still faces clinical bottlenecks such as high recurrence rates and difficulties with margin control. This article discusses current clinical difficulties and explores indication expansion and coping strategies for various ablation techniques. The "no touch" strategies of radiofrequency ablation and microwave ablation have shown an overall survival period that is comparable to that of surgery for medium or multiple tumors that are 3 to 5 cm in size. Microwave ablation and repeated surgical resection that meets the Milan criteria have similar overall and disease-free survival rates in patients with intrahepatic cholangiocarcinoma. Non-thermal ablation techniques such as irreversible electroporation offer safe alternatives for refractory lesions adjacent to large blood vessels or bile ducts due to their characteristics of no heat-sink effect and preservation of collagen scaffolds. Image fusion navigation and synergistic "ablation plus immunotherapy" may be key directions for overcoming local control bottlenecks and improving long-term prognosis in the future.

Indexed as

Carcinoma, HepatocellularCatheter AblationLiver NeoplasmsUltrasonography, InterventionalHumansRadiofrequency Ablation

Identifiers

PMID42373435
PMCPMC13312290

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.